CalciMedica
Recent Finacing
Series D
Recent Raise
$21M
CalciMedica is a clinical-stage biotechnology company that develops selective small-molecule CRAC channel inhibitors, advancing lead candidate Auxora in clinical trials for acute pancreatitis and COVID-19 pneumonia.
Highlights
Focus Areas
Health Care
Information Technology
Life Science
Recent Investors
Financials
$37.5M
Total Raised
4
Funding rounds
8
Investors